2023 World Conference on Lung Cancer (Posters)-EP13.07. Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy

EP13.07. Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

The Canadian Consensus Recommendations discuss the use of radiation therapy among patients with extensive-stage small cell lung cancer (ES-SCLC) receiving immunotherapy. The document highlights the efficacy of thoracic radiotherapy (TRT) and prophylactic cranial irradiation (PCI) in improving progression-free survival (PFS) and overall survival (OS) in ES-SCLC patients. It emphasizes that TRT can be effective for local control and survival benefit in ES-SCLC patients. The document also provides recommendations for the use of radiation therapy in ES-SCLC patients receiving immunotherapy.<br /><br />The consensus recommends that all patients who respond to concurrent chemo-immunotherapy should be considered for consolidation TRT. It suggests a dose of 30 Gy in 10 fractions for consolidation TRT, but acknowledges that a modified schedule may be appropriate based on patient characteristics and preferences. The optimal timing of consolidation TRT during immunotherapy should be after completion of concurrent chemo-immunotherapy.<br /><br />For patients without brain metastases, the consensus recommends considering PCI or MRI surveillance. It suggests that all patients who respond to concurrent chemo-immunotherapy should undergo restaging with brain MRI to guide decision-making. Patients with a response to concurrent chemo-immunotherapy, without brain metastases, and with good performance status (PS) should be considered for PCI. MRI surveillance should be conducted for 2 years after response to concurrent chemo-immunotherapy, with the frequency depending on the year. CT surveillance is an option if MRI is not feasible.<br /><br />The consensus also states that concurrent treatment with TRT, PCI, and immunotherapy is appropriate. It suggests that consolidation TRT and PCI should be provided after completion of concurrent chemo-immunotherapy. The optimal timing of TRT, PCI, and immunotherapy should be determined on a case-by-case basis.<br /><br />Overall, the Canadian Consensus Recommendations provide guidance on the use of radiation therapy in ES-SCLC patients receiving immunotherapy, emphasizing the importance of personalized treatment decisions and multidisciplinary collaboration.

Asset Subtitle

Alexander Sun

Meta Tag

Speaker Alexander Sun

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

Canadian Consensus Recommendations

radiation therapy

ES-SCLC

immunotherapy

TRT

PCI

progression-free survival

PFS

overall survival

chemo-immunotherapy